A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12201-12215

  Bolles, Meagan ^a   Deming, Damon ^a   Long, Kristin ^b   Agnihothram, Sudhakar ^c   Whitmore, Alan ^b   Ferris, Martin ^b   Funkhouser, William ^a   Gralinski, Lisa ^c   Totura, Allison ^a   Heise, Mark ^a,b   Baric, Ralph S ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DOUBLE INACTIVATED SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; INACTIVATED VIRUS VACCINE; NUCLEOCAPSID PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG;

AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FEMALE; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOPATHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME; STRAIN DIFFERENCE; VACCINE FAILURE; VIRUS LOAD; VIRUS PLAQUE; VIRUS REPLICATION; VULNERABLE POPULATION; ZOONOSIS;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PULMONARY EOSINOPHILIA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VACCINES, INACTIVATED; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

ANIMALIA; MUS; SARS CORONAVIRUS;

EID: 81255200507     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06048-11     Document Type: Article

References (67)

1. Becker, M. M., et al. 2008. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc. Natl. Acad. Sci. U. S. A. 105:19944-19949.
2. Bisht, H., et al. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101:6641-6646.
3. Booth, C., et al. 2003. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289:2801-2809.
4. Bossart, K. N., et al. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 5:e1000642.
5. Cameron, M., et al. 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in severe acute respiratory syndrome (SARS) patients. J. Virol. 81:8692-8706.
6. Castilow, E. M., K. L. Legge, and S. M. Varga. 2008. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181:6692-6696.
7. Chen, Z., et al. 2004. Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein. Clin. Chem. 50:988-995.
8. Chinese SARS Molecular Epidemiology Consortium. 2004. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303:1666-1669.
9. Chow, S. C. S., et al. 2006. Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. J. Clin. Pathol. 59:468-476.
10. Delgado, M. F., et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
11. Deming, D., et al. 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3:e525.
12. Donnelly, C. A., et al. 2003. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361:1761-1766.
13. Enjuanes, L., et al. 2008. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 133:45-62.
14. Goodwin, K., C. Viboud, and L. Simonsen. 2006. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159-1169.
15. Greenough, T. C., et al. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191:507-514.
16. Gruver, A. L., L. L. Hudson, and G. D. Sempowski. 2007. Immunosenescence of ageing. J. Pathol. 211:144-156.
17. He, Y., Y. Zhou, P. Siddiqui, and S. Jiang. 2004. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325:445-452.
18. HogenEsch, H. 2002. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20:S34-S39.
19. Hou, Y.-X., et al. 2010. Immunogenicity of the spike glycoprotein of Bat SARS-like coronavirus. Virol. Sin. 25:36-44.
20. Ishioka, T., et al. 2011. Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549). Cell Biol. Int. 35:467-474.
21. Kopecky-Bromberg, S. A., L. Martínez-Sobrido, M. Frieman, R. A. Baric, and P. Palese. 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81:548-557.
22. Lau, S. K. P., et al. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102:14040-14045.
23. Li, W., et al. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310:676-679.
24. Lin, J.-T., et al. 2007. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 12:1107-1113.
25. LoBue, A. D., J. M. Thompson, L. Lindesmith, R. E. Johnston, and R. S. Baric. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83:3212-3227.
26. Malcolm, K. C., et al. 2011. Bacteria-specific neutrophil dysfunction associated with interferon-stimulated gene expression in the acute respiratory distress syndrome. PLoS One 6:e21958.
27. Marshall, E., and M. Enserink. 2004. Medicine. Caution urged on SARS vaccines. Science 303:944-946.
28. Martin, J. E., et al. 2008. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 26:6338-6343.
29. McElhaney, J. E., J. W. Hooton, N. Hooton, and R. C. Bleackley. 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23:3294-3300.
30. Meyerholz, D. K., M. A. Griffin, E. M. Castilow, and S. M. Varga. 2009. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol. Pathol. 37:249-255.
31. Moghaddam, A., et al. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12:905-907.
32. Narasaraju, T., et al. 2011. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol. 179:199-210.
33. Netland, J., et al. 2010. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399:120-128.
34. Neuman, B. W., et al. 2006. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol. 80:7918-7928.
35. Normile, D. 2005. Virology researchers tie deadly SARS virus to bats. Science 309:2154-2155.
36. Peiris, J. S. M., et al. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767-1772.
37. Peng, H., L.-T. Yang, L.-Y. Wang, J. Li, J. Huang, Z.-Q. Lu, R. A. Koup, R. T. Bailer, and C.-Y Wu. 2006. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351:466-475.
38. Polack, F. 2007. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 62:111.
39. Roberts, A., et al. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3:e5.
40. Roberts, A., et al. 2010. Immunogenicity and protective efficacy in mice and hamsters of a
41. Roberts, A., et al. 2008. Animal models and vaccines for SARS-CoV infection. Virus Res. 133:20-32.
42. Roberts, A., et al. 2005. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 79:5833-5838.
43. Rockx, B., et al. 2009. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J. Virol. 83: 7062-7074.
44. Rockx, B., et al. 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82:3220-3235.
45. Rockx, B., et al. 2007. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J. Virol. 81:7410-7423.
46. See, R. H., et al. 2008. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J. Gen. Virol. 89:2136-2146.
47. Sheahan, T., D. Deming, E. Donaldson, R. Pickles, and R. Baric. 2006. Resurrection of an "extinct" SARS-CoV isolate GD03 from late 2003. Adv. Exp. Med. Biol. 581:547-550.
48. Sheahan, T., et al. 2011. Successful vaccination strategies that protect aged mice from lethal influenza and lethal heterologous SARS-CoV challenge. J. Virol. 85:217-230.
49. Song, H., et al. 2005. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci. U. S. A. 102:2430-2435.
50. Spruth, M., et al. 2006. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24:652-661.
51. Stockman, L. J., R. Bellamy, and P. Garner. 2006. SARS: systematic review of treatment effects. PLoS Med. 3:e343.
52. Subbarao, K., et al. 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78:3572-3577.
53. Takasuka, N., et al. 2004. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16:1423-1430.
54. Thompson, J. M., et al. 2006. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 103:3722-3727.
55. Thompson, J. M., A. C. Whitmore, H. F. Staats, and R. Johnston. 2008. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26:4998-5003.
56. Thompson, J. M., A. C. Whitmore, H. F. Staats, and R. E. Johnston. 2008. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 26:4267-4275.
57. Tsunetsugu-Yokota, Y., M. Ato, Y. Takahashi, S.-I. Hashimoto, T. Kaji, M. Kuraoka, K.-I. Yamamoto, Y.-Y. Mitsuki, T. Yamamoto, M. Oshima, K. Ohnishi, and T. Takemori. 2007. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses. Jpn. J. Infect. Dis. 60:106-112.
58. Ubol, S., and S. B. Halstead. 2010. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17: 1829-1835.
59. Vogel, L. N., et al. 2007. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine 25:2173-2179.
60. Yang, Z.-Y., et al. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561-564.
61. Yasui, F., et al. 2008. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181:6337-6348.
62. Yip, C. W., et al. 2009. Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. Infect. Genet. Evol. 9:1185-1196.
63. Yount, B., et al. 2003. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U. S. A. 100:12995-13000.
64. Zhang, J.-S., et al. 2005. A serological survey on neutralizing antibody titer of SARS convalescent sera. J. Med. Virol. 77:147-150.
65. Zhong, X., et al. 2005. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J. Virol. 79:3401-3408.
66. Zhu, Y. G., and J. M. Qu. 2009. Differential characteristics of the early stage of lung inflammation induced by SARS-CoV nucleocapsid protein related to age in the mouse. Inflamm. Res. 58:312-320.
67. Zhu, Z., et al. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128.